Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
47.70
-0.01 (-0.02%)
At close: Sep 17, 2025, 4:00 PM EDT
47.61
-0.09 (-0.19%)
After-hours: Sep 17, 2025, 5:15 PM EDT
Tourmaline Bio Stock Forecast
Stock Price Forecast
The 12 analysts that cover Tourmaline Bio stock have a consensus rating of "Hold" and an average price target of $47.04, which forecasts a -1.38% decrease in the stock price over the next year. The lowest target is $25 and the highest is $58.
Price Target: $47.04 (-1.38%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Tourmaline Bio stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 0 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy → Hold Downgrades $35 → $48 | Buy → Hold | Downgrades | $35 → $48 | +0.63% | Sep 15, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $65 → $48 | Buy → Hold | Downgrades | $65 → $48 | +0.63% | Sep 11, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $63 → $48 | Strong Buy → Hold | Downgrades | $63 → $48 | +0.63% | Sep 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades $55 → $48 | Strong Buy → Hold | Downgrades | $55 → $48 | +0.63% | Sep 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $70 → $48 | Strong Buy → Hold | Downgrades | $70 → $48 | +0.63% | Sep 10, 2025 |
Financial Forecast
Revenue This Year
7.65M
Revenue Next Year
7.65M
from 7.65M
EPS This Year
-3.53
from -2.89
EPS Next Year
-4.37
from -3.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.0M | 63.0M | |||
| Avg | 7.7M | 7.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 723.5% | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.89 | -3.06 | |||
| Avg | -3.53 | -4.37 | |||
| Low | -4.01 | -5.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.